Literature DB >> 33743615

Radiomic model for differentiating parotid pleomorphic adenoma from parotid adenolymphoma based on MRI images.

Le-le Song1, Shun-Jun Chen2, Wang Chen1, Zhan Shi1, Xiao-Dong Wang1, Li-Na Song3, Dian-Sen Chen4.   

Abstract

BACKGROUND: Distinguishing parotid pleomorphic adenoma (PPA) from parotid adenolymphoma (PA) is important for precision treatment, but there is a lack of readily available diagnostic methods. In this study, we aimed to explore the diagnostic value of radiomic signatures based on magnetic resonance imaging (MRI) for PPA and PA.
METHODS: The clinical characteristic and imaging data were retrospectively collected from 252 cases (126 cases in the training cohort and 76 patients in the validation cohort) in this study. Radiomic features were extracted from MRI scans, including T1-weighted imaging (T1WI) sequences and T2-weighted imaging (T2WI) sequences. The radiomic features from three sequences (T1WI, T2WI and T1WI combined with T2WI) were selected using univariate analysis, LASSO correlation and Spearman correlation. Then, we built six quantitative radiomic models using the selected features through two machine learning methods (multivariable logistic regression, MLR, and support vector machine, SVM). The performances of the six radiomic models were assessed and the diagnostic efficacies of the ideal T1-2WI radiomic model and the clinical model were compared.
RESULTS: The T1-2WI radiomic model using MLR showed optimal discriminatory ability (accuracy = 0.87 and 0.86, F-1 score = 0.88 and 0.86, sensitivity = 0.90 and 0.88, specificity = 0.82 and 0.80, positive predictive value = 0.86 and 0.84, negative predictive value = 0.86 and 0.84 in the training and validation cohorts, respectively) and its calibration was observed to be good (p > 0.05). The area under the curve (AUC) of the T1-2WI radiomic model was significantly better than that of the clinical model for both the training (0.95 vs. 0.67, p < 0.001) and validation (0.90 vs. 0.68, p = 0.001) cohorts.
CONCLUSIONS: The T1-2WI radiomic model in our study is complementary to the current knowledge of differential diagnosis for PPA and PA.

Entities:  

Mesh:

Year:  2021        PMID: 33743615      PMCID: PMC7981906          DOI: 10.1186/s12880-021-00581-9

Source DB:  PubMed          Journal:  BMC Med Imaging        ISSN: 1471-2342            Impact factor:   1.930


  32 in total

1.  Comprehensive Computed Tomography Radiomics Analysis of Lung Adenocarcinoma for Prognostication.

Authors:  Geewon Lee; Hyunjin Park; Insuk Sohn; Seung-Hak Lee; So Hee Song; Hyeseung Kim; Kyung Soo Lee; Young Mog Shim; Ho Yun Lee
Journal:  Oncologist       Date:  2018-04-05

Review 2.  Update 2018: 18F-FDG PET/CT and PET/MRI in Head and Neck Cancer.

Authors:  Yasemin Sanli; Katherine Zukotynski; Erik Mittra; Delphine L Chen; Helen Nadel; Ryan D Niederkohr; Rathan M Subramaniam
Journal:  Clin Nucl Med       Date:  2018-12       Impact factor: 7.794

3.  Prediction of Core Signaling Pathway by Using Diffusion- and Perfusion-based MRI Radiomics and Next-generation Sequencing in Isocitrate Dehydrogenase Wild-type Glioblastoma.

Authors:  Ji Eun Park; Ho Sung Kim; Seo Young Park; Soo Jung Nam; Sung-Min Chun; Youngheun Jo; Jeong Hoon Kim
Journal:  Radiology       Date:  2019-12-17       Impact factor: 11.105

Review 4.  Advances and challenges in precision medicine in salivary gland cancer.

Authors:  Gerben Lassche; Wim van Boxtel; Marjolijn J L Ligtenberg; Adriana C H van Engen-van Grunsven; Carla M L van Herpen
Journal:  Cancer Treat Rev       Date:  2019-10-14       Impact factor: 12.111

5.  Development and validation of a CT-based radiomic nomogram for preoperative prediction of early recurrence in advanced gastric cancer.

Authors:  Wenjuan Zhang; Mengjie Fang; Di Dong; Xiaoxiao Wang; Xiaoai Ke; Liwen Zhang; Chaoen Hu; Lingyun Guo; Xiaoying Guan; Junlin Zhou; Xiuhong Shan; Jie Tian
Journal:  Radiother Oncol       Date:  2019-12-21       Impact factor: 6.280

6.  Radiomics on multi-modalities MR sequences can subtype patients with non-metastatic nasopharyngeal carcinoma (NPC) into distinct survival subgroups.

Authors:  En-Hong Zhuo; Wei-Jing Zhang; Hao-Jiang Li; Guo-Yi Zhang; Bing-Zhong Jing; Jian Zhou; Chun-Yan Cui; Ming-Yuan Chen; Ying Sun; Li-Zhi Liu; Hong-Min Cai
Journal:  Eur Radiol       Date:  2019-03-14       Impact factor: 5.315

Review 7.  The Applications of Radiomics in Precision Diagnosis and Treatment of Oncology: Opportunities and Challenges.

Authors:  Zhenyu Liu; Shuo Wang; Di Dong; Jingwei Wei; Cheng Fang; Xuezhi Zhou; Kai Sun; Longfei Li; Bo Li; Meiyun Wang; Jie Tian
Journal:  Theranostics       Date:  2019-02-12       Impact factor: 11.556

8.  A multipredictor model to predict the conversion of mild cognitive impairment to Alzheimer's disease by using a predictive nomogram.

Authors:  Kexin Huang; Yanyan Lin; Lifeng Yang; Yubo Wang; Suping Cai; Liaojun Pang; Xiaoming Wu; Liyu Huang
Journal:  Neuropsychopharmacology       Date:  2019-10-21       Impact factor: 7.853

Review 9.  The Potential of Radiomic-Based Phenotyping in Precision Medicine: A Review.

Authors:  Hugo J W L Aerts
Journal:  JAMA Oncol       Date:  2016-12-01       Impact factor: 31.777

10.  Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study.

Authors:  Ralph Th Leijenaar; Marta Bogowicz; Arthur Jochems; Frank Jp Hoebers; Frederik Wr Wesseling; Sophie H Huang; Biu Chan; John N Waldron; Brian O'Sullivan; Derek Rietveld; C Rene Leemans; Ruud H Brakenhoff; Oliver Riesterer; Stephanie Tanadini-Lang; Matthias Guckenberger; Kristian Ikenberg; Philippe Lambin
Journal:  Br J Radiol       Date:  2018-03-22       Impact factor: 3.039

View more
  1 in total

1.  Differentiation of Benign From Malignant Parotid Gland Tumors Using Conventional MRI Based on Radiomics Nomogram.

Authors:  Jinbo Qi; Ankang Gao; Xiaoyue Ma; Yang Song; Guohua Zhao; Jie Bai; Eryuan Gao; Kai Zhao; Baohong Wen; Yong Zhang; Jingliang Cheng
Journal:  Front Oncol       Date:  2022-07-11       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.